CEO Chris Boerner buys shares as stock slumps
- Bristol Myers Squibb CEO Chris Boerner buys company stock
- Boerner purchased 3,071 shares at an average price of $48.86
- Boerner now owns 79,384 shares in a personal account
- Bristol Myers stock has lost about a third of its value this year
- Boerner’s purchase follows another insider buy by Bristol Myers director Theodore R. Samuels
Bristol Myers Squibb CEO Chris Boerner recently made a notable purchase of the company’s stock. Boerner bought 3,071 shares at an average price of $48.86, bringing his total ownership to 79,384 shares in a personal account. This purchase comes at a time when Bristol Myers stock has experienced a significant decline, losing about a third of its value this year. Boerner’s decision to buy shares follows a similar move by Bristol Myers director Theodore R. Samuels. Samuels purchased 8,500 shares at an average price of $49.81. These insider buys indicate confidence in the company’s future prospects despite the current stock performance.
Factuality Level: 8
Factuality Justification: The article provides specific details about the CEO’s stock purchase, including the date, number of shares, and price. It also mentions the CEO’s previous stockholdings and the decline in the company’s stock value. The information is based on a form filed with the Securities and Exchange Commission. However, the article does not provide any analysis or context for the stock purchase, and it does not include any comments or statements from the CEO or other sources.
Noise Level: 3
Noise Justification: The article provides information about the CEO of Bristol Myers Squibb buying a large block of the company’s shares. It mentions the price and number of shares purchased, as well as the CEO’s current stock ownership. It also mentions that the stock has lost value this year. However, the article lacks analysis, context, and actionable insights. It does not explore the reasons behind the stock slump or the potential implications of the CEO’s purchase. Overall, the article is short and lacks depth.
Financial Relevance: Yes
Financial Markets Impacted: Bristol Myers stock
Presence Of Extreme Event: No
Nature Of Extreme Event: No
Impact Rating Of The Extreme Event: No
Rating Justification: The article pertains to financial topics as it discusses the CEO of Bristol Myers Squibb purchasing the company’s stock. However, there is no mention of any extreme event or its impact.
Public Companies: Bristol Myers Squibb (BMY)
Key People: Chris Boerner (CEO), Theodore R. Samuels (Director)
Reported publicly:
www.marketwatch.com 
